First dose of misoprostol administration at home or in hospital for medical abortion between 12–22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial
- 29 August 2024
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 404 (10455) , 864-873
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- COVID-19 impact in abortions’ practice, a regional French evaluationJournal of Gynecology Obstetrics and Human Reproduction, 2021
- Medical abortion at 13 or more weeks gestation provided through telemedicine: A retrospective review of servicesContraception: X, 2021
- Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysisContraception: X, 2020
- Feasibility of a hospital outpatient day procedure for medication abortion at 13–18 weeks gestation: Findings from Nepal,Contraception, 2019
- Could second-trimester medical abortion be offered as a day service? Assessing the feasibility of a 1-day outpatient procedure using pooled data from six clinical studiesContraception, 2019
- A double‐blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14–21 weeks of pregnancyInternational Journal of Gynecology & Obstetrics, 2015
- Provision of medical abortion using telemedicine in BrazilContraception, 2014
- Second Trimester Medical Abortion with Mifepristone–Misoprostol and Misoprostol Alone: A Review of Methods and ManagementReproductive Health Matters, 2008
- Midtrimester medical termination of pregnancy: a review of 1002 consecutive casesContraception, 2004
- Outpatient second trimester pregnancy terminationContraception, 2001